Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Old dogma, new tricks—21st Century phage therapy

Nature Biotechnology volume 22, pages 31–36 (2004)Cite this article

As antibiotic resistant bacteria threaten a public health crisis, biotechnology is turning to bacteriophages, nature's tiniest viruses. But can phage therapy overcome its historical baggage?

Resistance rising

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Figure 1: Phage life cycle.

R. Henretta

Figure 2: Phage pioneers.
Figure 3: Lysis to kill.

References

  1. US Centers for Disease Control, the Food and Drug Administration and the US National Institutes of Health. A Public Health Action Plan to Combat Antimicrobial Resistance (CDC, FDA & NIH, June, 2000) (http://www.cdc.gov/drugresistance/ actionplan/aractionplan.pdf).

  2. S. Tslodras et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358, 207–208 (2001).

    Article  Google Scholar 

  3. G.M. Eliopoulos, et al. Characterization of vancomycin-resistant Enterococcus faecium isolates from the United States and their susceptibility in vitro to dalfopristin-quinupristin. Antimicrobial Agents Chemother. 42, 1088–1092 (1998).

    CAS  Article  Google Scholar 

  4. Fox, J. Concerns raised over declining antiinfective R&D. Nat. Biotechnol. 21, 1255–1256 (2003).

    CAS  Article  Google Scholar 

  5. Scholl, D. et al. Bacteriophage K1-5 encodes two different tail fiber proteins, allowing it to infect and replicate on both K1 and K5 strains of Escherichia coli. J. Virol. 75, 2509–2515 (2001).

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. freelance writer based, Portland, Oregon, USA

    Karl Thiel

Authors
  1. Karl Thiel
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Thiel, K. Old dogma, new tricks—21st Century phage therapy. Nat Biotechnol 22, 31–36 (2004). https://doi.org/10.1038/nbt0104-31

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0104-31

Further reading

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing